Cargando…

Cannabidiol modulation of hippocampal glutamate in early psychosis

BACKGROUND: Emerging evidence supports the antipsychotic effect of cannabidiol, a non-intoxicating component of cannabis, in people with psychosis. Preclinical findings suggest that this antipsychotic effect may be related to cannabidiol modulating glutamatergic signalling in the brain. AIM: The pur...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Neill, Aisling, Annibale, Luciano, Blest-Hopley, Grace, Wilson, Robin, Giampietro, Vincent, Bhattacharyya, Sagnik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278563/ https://www.ncbi.nlm.nih.gov/pubmed/33860709 http://dx.doi.org/10.1177/02698811211001107

Ejemplares similares

O5.2. CBD MODULATION OF HIPPOCAMPAL GLUTAMATE IN PSYCHOSIS
por: O’Neill, Aisling, et al.
Publicado: (2020)

S152. CANNABIDIOL INDUCED MODULATION OF MEDIOTEMPORAL ACTIVITY DURING A VERBAL MEMORY TASK IN FIRST-EPISODE PSYCHOSIS
por: O’Neill, Aisling, et al.
Publicado: (2018)

T99. LONG-TERM CANNABIS USE ASSOCIATED WITH ALTERED FUNCTIONING DURING VERBAL LEARNING
por: Blest-Hopley, Grace, et al.
Publicado: (2018)

Disrupted parahippocampal and midbrain function underlie slower verbal learning in adolescent-onset regular cannabis use
por: Blest-Hopley, Grace, et al.
Publicado: (2019)

Regular cannabis use is associated with altered activation of central executive and default mode networks even after prolonged abstinence in adolescent users: Results from a complementary meta-analysis
por: Blest-Hopley, Grace, et al.
Publicado: (2019)

A Systematic Review of Human Neuroimaging Evidence of Memory-Related Functional Alterations Associated with Cannabis Use Complemented with Preclinical and Human Evidence of Memory Performance Alterations
por: Blest-Hopley, Grace, et al.
Publicado: (2020)

A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis
por: Davies, Cathy, et al.
Publicado: (2020)

Is the Adolescent Brain at Greater Vulnerability to the Effects of Cannabis? A Narrative Review of the Evidence
por: Blest-Hopley, Grace, et al.
Publicado: (2020)

Epigenetic Mediation of AKT1 rs1130233’s Effect on Delta-9-Tetrahydrocannabinol-Induced Medial Temporal Function during Fear Processing
por: Blest-Hopley, Grace, et al.
Publicado: (2021)

Cannabidiol as a potential treatment for psychosis
por: Davies, Cathy, et al.
Publicado: (2019)

Association of cannabis with glutamatergic levels in patients with early psychosis: Evidence for altered volume striatal glutamate relationships in patients with a history of cannabis use in early psychosis
por: Sami, Musa, et al.
Publicado: (2020)

17. CANNABIDIOL AS A TREATMENT IN DIFFERENT STAGES OF PSYCHOSIS- EFFICACY AND MECHANISMS
por: Bhattacharyya, Sagnik
Publicado: (2018)

Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders
por: Blest-Hopley, Grace, et al.
Publicado: (2023)

T145. EFFECTS OF CANNABIDIOL ON EMOTION PROCESSING IN PSYCHOSIS RISK: AN FMRI INVESTIGATION
por: Davies, Cathy, et al.
Publicado: (2020)

Altered relationship between cortisol response to social stress and mediotemporal function during fear processing in people at clinical high risk for psychosis: a preliminary report
por: Davies, Cathy, et al.
Publicado: (2021)

Eye movements in patients in early psychosis with and without a history of cannabis use
por: Sami, Musa Basseer, et al.
Publicado: (2021)

Human Striatal Response to Reward Anticipation Linked to Hippocampal Glutamate Levels
por: Bossong, Matthijs G, et al.
Publicado: (2018)

Cannabis use in patients with early psychosis is associated with alterations in putamen and thalamic shape
por: Sami, Musa, et al.
Publicado: (2020)

17.3 EFFECT OF CANNABIDIOL ON SYMPTOMS, DISTRESS AND NEUROPHYSIOLOGICAL ABNORMALITIES IN CLINICAL HIGH-RISK FOR PSYCHOSIS PATIENTS: A PLACEBO-CONTROLLED STUDY
por: Bhattacharyya, Sagnik, et al.
Publicado: (2018)

Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis
por: Wilson, Robin, et al.
Publicado: (2019)

Delta-9-tetrahydrocannabinol increases striatal glutamate levels in healthy individuals: implications for psychosis
por: Colizzi, Marco, et al.
Publicado: (2019)

Does Cannabis Composition Matter? Differential Effects of Delta-9-tetrahydrocannabinol and Cannabidiol on Human Cognition
por: Colizzi, Marco, et al.
Publicado: (2017)

F102. CHANGE IN PATTERNS OF CANNABIS AND OTHER SUBSTANCE USE OVER TIME IN EARLY PSYCHOSIS- EXAMINING THE EFFECT OF DEVELOPMENT OF PSYCHOSIS
por: Sami, Musa, et al.
Publicado: (2018)

Acceptability of cannabidiol in patients with psychosis
por: Chesney, Edward, et al.
Publicado: (2022)

Cannabinoids, reward processing, and psychosis
por: Gunasekera, Brandon, et al.
Publicado: (2021)

17.2 EFFICACY OF CANNABIDIOL IN THE TREATMENT OF EARLY PSYCHOSIS.
por: Ranganathan, Mohini, et al.
Publicado: (2018)

M163. GLUTAMATE METABOLITES ARE ASSOCIATED WITH ALTERED HIPPOCAMPAL ACTIVATION BUT NOT HIPPOCAMPAL-STRIATAL CONNECTIVITY IN SUBJECTS WITH A CLINICAL HIGH RISK FOR PSYCHOSIS
por: Hird, Emily, et al.
Publicado: (2020)

Cannabidiol (CBD) as a novel treatment in the early phases of psychosis
por: Chesney, Edward, et al.
Publicado: (2021)

Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition
por: Colizzi, Marco, et al.
Publicado: (2020)

Cannabidiol Keeps Hippocampal Hyperactivity in Check
por: Wong, Jennifer C.
Publicado: (2023)

Hippocampal glutamate and hippocampus subfield volumes in antipsychotic-naive first episode psychosis subjects and relationships to duration of untreated psychosis
por: Briend, Frédéric, et al.
Publicado: (2020)

A Comparison of Cognitive Performance in Patients With Parkinson's Disease Psychosis According to Psychosis Severity: A Meta-Analysis
por: Gosse, Luca, et al.
Publicado: (2023)

Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis
por: Appiah-Kusi, E., et al.
Publicado: (2020)

Hippocampal circuit dysfunction in psychosis
por: Knight, Samuel, et al.
Publicado: (2022)

Alterations in White Matter Evident Before the Onset of Psychosis
por: Carletti, Francesco, et al.
Publicado: (2012)

The Autism–Psychosis Continuum Conundrum: Exploring the Role of the Endocannabinoid System
por: Colizzi, Marco, et al.
Publicado: (2022)

M169. HIPPOCAMPAL GLUTAMATE AND HIPPOCAMPUS SUBFIELD VOLUMES IN ANTIPSYCHOTIC-NAIVE FIRST EPISODE PSYCHOSIS SUBJECTS AND RELATIONSHIPS TO DURATION OF UNTREATED PSYCHOSIS
Publicado: (2020)

Association of cannabis use with hospital admission and antipsychotic treatment failure in first episode psychosis: an observational study
por: Patel, Rashmi, et al.
Publicado: (2016)

Correction: Hippocampal circuit dysfunction in psychosis
por: Knight, Samuel, et al.
Publicado: (2022)

Biphasic Modulation of NMDA Receptor Function by Metabotropic Glutamate Receptors
por: O'Neill, Nathanael, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k7utfpruas0j6qk1nbhs67q4co